via QIMR Berghofer
QIMR Berghofer researchers have discovered a potential new cancer immunotherapy target that involves switching off a regulatory cell to stop tumours growing and spreading.
The study findings have been published today in Cancer Discovery, a journal of the American Association for Cancer Research.
Senior researcher and head of QIMR Berghofer’s Cancer Immunoregulation and Immunotherapy Laboratory, Associate Professor Michele Teng, said in future the discovery could potentially help treat patients with cancers where other current immunotherapies have not worked.
“Our work on mice shows for the first time that many tumours display the molecule MR1 on their cell surface, and when it’s present, this molecule turns on an important regulatory cell that prevents the body’s own immune system from fighting the cancer,” Associate Professor Teng said.
“We found if a type of regulatory cell called MAIT (mucosal-associated invariant T) cells are turned on, they stop immune or white blood cells known as T and NK cells from attacking and killing off tumour cells.
“The cancer is effectively creating its own defence mechanism to evade immune attack and survive. The display of MR1 activates the MAIT cells, which in turn switch off cancer-fighting T and NK cells.
“While other regulatory cells of the immune system are known to stop T and NK cells from killing tumour cells, this is the first time it’s been shown that these regulatory MAIT cells can do this job.”
Associate Professor Teng said her team found that by giving mice an antibody that blocked MR1, this stopped the MAIT cells from becoming activated, and the T and NK cells could respond, slowing cancer growth and stopping it spreading.
“This work demonstrates that antibodies that block MR1 could in future be an effective new immunotherapy,” Associate Professor Teng said.
“It probably won’t work on every cancer, but it looks like it could be effective in treating cancers that can display the MR1 molecule. It also means this display of MR1 could be used to screen which patients would respond to this immunotherapy.
“We now need to replicate this research in humans.”
Associate Professor Teng said while the research was at a very early stage and required more work, it was promising.
“The next step is to try to understand what kind of human tumours display MR1 as a protective mechanism, which would then help us identify which tumours would respond best to MR1-blocking immunotherapy,” she said.
“Immunotherapies have been effectively used to treat more than 15 different cancer types but the proportion of patients that respond for each cancer can differ.
“In patients with advanced melanoma for example, current approved immunotherapies work in about 50 per cent of cases, but half do not respond, and that’s why we need to find new therapies.”
Learn more: POTENTIAL NEW CANCER TREATMENT A STEP CLOSER
Go deeper with Bing News on:
Cancer immunotherapy
- Cancer drug developer Kairos Pharma files for IPO
Immunotherapy developer Kairos Pharma (KAPA ... Based in Los Angeles, Kairos' lead drug candidate, ENV105, is in Phase 2 testing for prostate cancer and Phase 1 testing for EGFR-dependent non-small ...
- Scientists find way to inhibit side effect of cancer immunotherapy
The CRS, also known as cytokine storm, is an overreaction of the immune system. It happens as an adverse effect of certain types of immunotherapy, such as CAR T-cell therapy, which can efficiently ...
- Scientists developing implant to cure cancer in just 60 days — with goal to slash death rates by 50%
The aim is to improve the outcomes of immunotherapy treatments for cancers that are usually difficult to treat.
- Neoadjuvant immunotherapy shows promise in multiple cancer types
Treating cancer with immunotherapies known as an immune checkpoint blockade (ICB) prior to surgery (so-called neoadjuvant immunotherapy) has been a rapidly growing area of research, but the scientific ...
- How 10 Ovarian Cancer Survivors Got Diagnosed
After my debulking surgery (a second surgery that lasted six hours), my ovarian cancer diagnosis changed to stage 3A. I achieved a brief remission after having gone through chemotherapy, and am ...
Go deeper with Google Headlines on:
Cancer immunotherapy
[google_news title=”” keyword=”cancer immunotherapy” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Blocking immunotherapy
- Cimeio Therapeutics Announces Publication of Seminal Epitope Editing Work in the Journal of Experimental Medicine
Cimeio Therapeutics, a biotechnology company that is reimagining immunotherapy with its Shielded Cell and Immunotherapy (SCIP®) platform, along with Prof. Lukas Jeker’s team at the Department of ...
- 6 Immuno-oncology Startups Attracting the Biggest VC Cash
Check out Inside Precision Medicine's list of six private immuno-oncology startups around the world that have raised the biggest funding rounds in the last two years.
- Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023
Title: PYX-102, an Anti-KLRG1 Antibody, Enhances Cytotoxic Activity of CD8 T cells from PBMC and Human Tumor Samples by Blocking the Interaction Between KLRG1 and Cadherins Poster Number: 572 Session ...
- Kineta to Present New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy
Blocking VISTA induces an efficient polyfunctional immune response to address immunosuppression and drives anti-tumor responses. This press release contains “forward-looking statements” within ...
- Combo Immunotherapy With Durvalumab Effective for NSCLC
For patients with resectable non-small cell lung cancer (NSCLC), combination immunotherapy with the anti-programmed death-ligand 1 monoclonal antibody durvalumab and other novel agents ...
Go deeper with Google Headlines on:
Blocking immunotherapy
[google_news title=”” keyword=”blocking immunotherapy” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
